Hepion Pharmaceuticals Appoints Dr. Kaouthar Lbiati as CEO with Compensation Tied to $3M Equity Financing
summarizeSummary
Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as CEO, whose compensation includes deferred salary contingent on securing a minimum $3 million equity financing, signaling a critical need for capital and new strategic direction.
check_boxKey Events
-
New CEO Appointment
Dr. Kaouthar Lbiati was appointed Chief Executive Officer, effective January 8, 2026.
-
Compensation Structure
Dr. Lbiati will receive an annual base salary of $350,000 and a target annual cash bonus of 35% of her base salary.
-
Financing Incentive
$50,000 of her base salary is deferred and payable upon the successful completion of an equity financing of at least $3,000,000.
-
Change of Control Bonus
A bonus of 3.0% of Enterprise Value is accrued if a Change of Control occurs with an Enterprise Value of at least $5,000,000.
auto_awesomeAnalysis
The appointment of Dr. Kaouthar Lbiati as CEO signals a new leadership direction for Hepion Pharmaceuticals. Her compensation structure, particularly the deferred salary contingent on a minimum $3 million equity financing, highlights the company's critical need for capital and incentivizes the new CEO to secure it. For a company of this size, successful financing is paramount for continued operations and drug development. Investors will be watching for updates on this financing and the new CEO's strategic initiatives.
At the time of this filing, HEPA was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $697.2K. The 52-week trading range was $0.03 to $1,325.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.